Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D000086582', 'term': 'Anosmia'}], 'ancestors': [{'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D000857', 'term': 'Olfaction Disorders'}, {'id': 'D012678', 'term': 'Sensation Disorders'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'sweat samples'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 100}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2012-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-06', 'lastUpdateSubmitDate': '2013-06-02', 'studyFirstSubmitDate': '2012-01-27', 'studyFirstSubmitQcDate': '2012-02-06', 'lastUpdatePostDateStruct': {'date': '2013-06-04', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2012-02-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of patients with lung neoplasms', 'timeFrame': 'one year', 'description': 'Dogs ability to distinguish between COPD and lung cancer patients sweat samples'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['lung neoplasms', 'dogs', 'sweat', 'smell'], 'conditions': ['Lung Neoplasms']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to show that dogs are able to detect cancer in sweat samples. This potentially would be the base for developing a new efficient, non invasive and inexpensive diagnosis tool of lung cancer.', 'detailedDescription': 'Among all cancers which harm the population, lung cancer is the most lethal type, responsible for 1.3 million deaths per year worldwide, for 28% of all cancer deaths.The 5 year survival rates are low, only 15%.\n\nDiagnosis and treatment of lung cancer in its early stages could increase the 5-year-survival rate by 3-4 fold with a potential for cure. Therefore, efforts are being made to develop new sensitive specified screening tools for detecting lung cancer at its\' earliest stages.\n\nA new emerging strategy for early detection of lung cancer is based on the recognition of the tumors metabolic signature, on the identification of specific biomarkers for the disease, such as the volatile organic compounds (VOC). Research has demonstrated that these compounds are released from the cancerous tissue from the early stages of the disease, and can be found in different bodily secretions.\n\nThe subjects, lung cancer patients and chronic obstructive pulmonary disease (COPD) patients, would be given cotton T-shirts with instructions to wear them without previously applying deodorant or any other similar personal hygiene products. Then, the shirts would be collected and 8 pieces (size:1cm\\*3cm from the armpit areas) would be cut from each one.\n\nDogs for this study would be trained by the "Dogs for People" association. In the initial stage, 40 mixed breed dogs and 3-4 Springer spaniels would be exposed to sweat sample collected from cancer patients in order to get them acquainted with the scent. Then, it would be demanded of them to locate boxes containing T-shirt sample taken from cancer patients, from decoy boxes holding naïve T-shirts. Every sequence will include 4 boxes with a different ratio between the specimens(each time a different number of boxes will contain samples taken from cancer patients, 0,1,2,3 or 4 when the rest of the boxes would contain naïve T-shirts). The dogs would mark the specimen by sitting next to each relevant box (they will ignore the decoy boxes after sniffing them and identifying them as irrelevant).\n\nThe most prominent 8-9 dogs would continue to the experiment phase. Each training course would last for 5-10 minutes or for 8 successful identifications, depending on the training dog needs. Dogs would be rewarded with a treat (a dog biscuit) or with play time, depending on the dogs\' nature.\n\nIn the experimental phase, the decoy boxes would hold sweat samples collected from COPD patients instead of naïve T-shirts. The dogs would be asked to locate boxes containing the T-shirt sample taken from the lung cancer patients, from the decoy boxes. Every sequence will include 4 boxes with a different ratio between the specimens (each time a different number of boxes will contain samples taken from cancer patients, 0,1,2,3 or 4 when the rest of the boxes would contain samples collected from COPD patients). The dogs would mark the specimen by sitting next to each relevant box (they will ignore the decoy boxes after sniffing them and identifying them as irrelevant).\n\nThe trainer would be oblivious to the targets\' location.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'The recruitment process will take place at the lung department of Sheba medical center. The participating physicians will enroll the patients and sing them on the consent form when they come for their regular appointments.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n• A diagnosis of lung cancer, regardless of histology.\n\nExclusion Criteria\n\n* Inability to comply with study and/or follow up procedure.\n* Co morbidity of lung cancer and an additional malignancy combined.\n* Patients taking part in another clinical trial and receiving any treatment for it.'}, 'identificationModule': {'nctId': 'NCT01527461', 'briefTitle': 'Identifying Unique Scent Signature of Lung Cancer Through Body Odor', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Sheba Medical Center'}, 'orgStudyIdInfo': {'id': 'SHEBA-11-9031-NP-CTIL'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Lung Cancer Patients', 'description': 'diagnosed lung cancer patients .'}, {'label': 'COPD Patients', 'description': 'COPD patients, not diagnosed with lung cancer.'}]}, 'contactsLocationsModule': {'locations': [{'zip': '52621', 'city': 'Tel Hasomer', 'status': 'RECRUITING', 'country': 'Israel', 'contacts': [{'name': 'Nir Peled, MD Phd FCCP', 'role': 'CONTACT', 'email': 'nir.peled@gmail.com', 'phone': '97235307014'}, {'name': 'Michal Alumot, M.Sc,RD', 'role': 'CONTACT', 'email': 'michalalumot@gmail.com', 'phone': '97235307009'}, {'name': 'Tal Frenkel, B.Sc', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Sheba Medical Center'}], 'centralContacts': [{'name': 'Nir Peled, MD PhD FCCP', 'role': 'CONTACT', 'email': 'peled.nir@gmail.com', 'phone': '972-3-5307014'}, {'name': 'Michal Alumot, M.Sc,RD', 'role': 'CONTACT', 'email': 'michalalumot@gmail.com', 'phone': '972-3-5307009'}], 'overallOfficials': [{'name': 'Nir Peled, MD PhD FCCP', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Sheba Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sheba Medical Center', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Head, Thoracic Cancer Research and Detection Center,Tel Hashomer, Israel', 'investigatorFullName': 'Dr. Nir Peled MD, PhD', 'investigatorAffiliation': 'Sheba Medical Center'}}}}